Monashee Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Monashee Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500,000	Closed	-$1.88M	–	24
2026 Q1	$1.88M	Buy	+500,000	New	+$1.69M	1.02%	33
2025 Q2	–	Sell	-888,888	Closed	-$1.36M	–	58
2025 Q1	$1.36M	Hold	888,888	–	–	0.16%	45
2024 Q4	$2.2M	Buy	+888,888	New	+$2.21M	0.3%	27
2021 Q3	–	Sell	-100,000	Closed	-$1.76M	–	266
2021 Q2	$1.76M	Buy	+100,000	New	+$2.27M	0.21%	141
2017 Q4	–	Hold	0	–	–	–	61
2017 Q3	–	Sell	-45,740	Closed	-$1.23M	–	43
2017 Q2	$1.24M	Buy	+45,740	New	+$1.24M	0.52%	51
2017 Q1	–	Sell	-126,700	Closed	-$3.65M	–	56
2016 Q4	$3.44M	Buy	+126,700	New	+$3.23M	1.67%	23
2016 Q3	–	Hold	0	–	–	–	64
2016 Q2	–	Hold	0	–	–	–	18

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Monashee Investment Management's ACRS Position: Q2 2026 in Review

Monashee Investment Management sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 500,000 shares — an estimated $1.88M sold.

Monashee Investment Management first reported a position in ACRS in Q4 2016 and held it in 6 quarters. The position peaked at $3.44M in Q4 2016. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Monashee Investment Management reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
Monashee Investment Management sold 500,000 Aclaris Therapeutics shares in Q2 2026, an estimated $1.88M.
Monashee Investment Management first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 6 quarters.
Monashee Investment Management's Aclaris Therapeutics position peaked at $3.44M in Q4 2016.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.